{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:57:49Z","timestamp":1758193069282,"version":"3.44.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,17]]},"DOI":"10.7759\/cureus.92594","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T06:01:04Z","timestamp":1758175264000},"source":"Crossref","is-referenced-by-count":0,"title":["Indian Clinicians\u2019 Perspectives on Utilizing Dapagliflozin-Based Combination Therapy for the Management of Obesity in Patients With Type 2 Diabetes Mellitus"],"prefix":"10.7759","author":[{"given":"Mayur","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhay","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raman","family":"Boddula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Baidya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiteswar","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prem","family":"Naryanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"R","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Modhugu N","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan N","family":"Kesarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijit","family":"Pednekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_1255_23","article-title":"Unravelling the obesity maze in diabetic patients: a comparative analysis of classification methods","volume":"13","author":"Yogesh M","year":"2024","unstructured":"Yogesh M, Mody M, Makwana N, Shah S, Patel J, Rabadiya S. Unravelling the obesity maze in diabetic patients: a comparative analysis of classification methods. J Family Med Prim Care. 2024, 13:2283-8. 10.4103\/jfmpc.jfmpc_1255_23","journal-title":"J Family Med Prim Care"},{"key":"ref2","unstructured":"Obesity and overweight. (2025). Accessed. February 27, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.9.1414","article-title":"Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections","volume":"21","author":"King H","year":"1998","unstructured":"King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998, 21:1414-31. 10.2337\/diacare.21.9.1414","journal-title":"Diabetes Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031882","article-title":"The role of obesity in type 2 diabetes mellitus-an overview","volume":"25","author":"Chandrasekaran P","year":"2024","unstructured":"Chandrasekaran P, Weiskirchen R. The role of obesity in type 2 diabetes mellitus-an overview. Int J Mol Sci. 2024, 25:1882. 10.3390\/ijms25031882","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0972753120987465","article-title":"Prevalence of obesity in India and its neurological implications: a multifactor analysis of a nationwide cross-sectional study","volume":"27","author":"Venkatrao M","year":"2020","unstructured":"Venkatrao M, Nagarathna R, Majumdar V, Patil SS, Rathi S, Nagendra H. Prevalence of obesity in India and its neurological implications: a multifactor analysis of a nationwide cross-sectional study. Ann Neurosci. 2020, 27:153-61. 10.1177\/0972753120987465","journal-title":"Ann Neurosci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.deman.2023.100155","article-title":"Association between abdominal obesity and diabetes in India: findings from a nationally representative study","volume":"12","author":"Gupta RD","year":"2023","unstructured":"Gupta RD, Kothadia RJ, Parray AA. Association between abdominal obesity and diabetes in India: findings from a nationally representative study. Diabet Epidemiol Manag. 2023, 12:100155. 10.1016\/j.deman.2023.100155","journal-title":"Diabet Epidemiol Manag"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-006351","article-title":"Economic impacts of overweight and obesity: current and future estimates for eight countries","volume":"6","author":"Okunogbe A","year":"2021","unstructured":"Okunogbe A, Nugent R, Spencer G, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for eight countries. BMJ Glob Health. 2021, 6:e006351. 10.1136\/bmjgh-2021-006351","journal-title":"BMJ Glob Health"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5551\/jat.40873","article-title":"Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes","volume":"25","author":"Sugiyama S","year":"2018","unstructured":"Sugiyama S, Jinnouchi H, Kurinami N, et al.. Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes. J Atheroscler Thromb. 2018, 25:467-76. 10.5551\/jat.40873","journal-title":"J Atheroscler Thromb"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s43042-022-00346-1","article-title":"Genetics of type 2 diabetes mellitus in Indian and global population: a review","volume":"23","author":"Joseph A","year":"2022","unstructured":"Joseph A, Thirupathamma M, Mathews E, Alagu M. Genetics of type 2 diabetes mellitus in Indian and global population: a review. Egypt J Med Hum Genet. 2022, 23:135. 10.1186\/s43042-022-00346-1","journal-title":"Egypt J Med Hum Genet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-022-01748-1","article-title":"Predictors for successful weight reduction during treatment with dapagliflozin among patients with type 2 diabetes mellitus in primary care","volume":"23","author":"Huh Y","year":"2022","unstructured":"Huh Y, Kim YS. Predictors for successful weight reduction during treatment with dapagliflozin among patients with type 2 diabetes mellitus in primary care. BMC Prim Care. 2022, 23:134. 10.1186\/s12875-022-01748-1","journal-title":"BMC Prim Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jand.2015.02.031","article-title":"Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"115","author":"Franz MJ","year":"2015","unstructured":"Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet. 2015, 115:1447-63. 10.1016\/j.jand.2015.02.031","journal-title":"J Acad Nutr Diet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-Sint01","article-title":"Introduction: standards of medical care in diabetes-2019","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Introduction: standards of medical care in diabetes-2019. Diabetes Care. 2019, 42:S1-2. 10.2337\/dc19-Sint01","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4158\/CS-2017-0153","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary","volume":"24","author":"Garber AJ","year":"2018","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, et al.. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary. Endocr Pract. 2018, 24:91-120. 10.4158\/CS-2017-0153","journal-title":"Endocr Pract"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2024.12461","article-title":"Effects of dapagliflozin on body weight in patients with type 2 diabetes mellitus: evidence\u2011based practice","volume":"27","author":"Han Y","year":"2024","unstructured":"Han Y, Li YF, Ye CW, et al.. Effects of dapagliflozin on body weight in patients with type 2 diabetes mellitus: evidence\u2011based practice. Exp Ther Med. 2024, 27:173. 10.3892\/etm.2024.12461","journal-title":"Exp Ther Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12239","article-title":"Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis","volume":"16","author":"Goring S","year":"2014","unstructured":"Goring S, Hawkins N, Wygant G, Roudaut M, Townsend R, Wood I, Barnett AH. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab. 2014, 16:433-42. 10.1111\/dom.12239","journal-title":"Diabetes Obes Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0052","article-title":"Use of dapagliflozin in the management of type 2 diabetes mellitus: a real-world evidence study in Indian patients (FOREFRONT)","volume":"21","author":"Viswanathan V","year":"2019","unstructured":"Viswanathan V, Singh KP. Use of dapagliflozin in the management of type 2 diabetes mellitus: a real-world evidence study in Indian patients (FOREFRONT). Diabetes Technol Ther. 2019, 21:415-22. 10.1089\/dia.2019.0052","journal-title":"Diabetes Technol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-023-00398-8","article-title":"Effectiveness of dapagliflozin as add-on to metformin with or without other oral antidiabetic drugs in type 2 diabetes mellitus: a multicentre, retrospective, real-world database study","volume":"11","author":"Sethi B","year":"2024","unstructured":"Sethi B, Sahay R, Tiwaskar M, et al.. Effectiveness of dapagliflozin as add-on to metformin with or without other oral antidiabetic drugs in type 2 diabetes mellitus: a multicentre, retrospective, real-world database study. Drugs Real World Outcomes. 2024, 11:81-90. 10.1007\/s40801-023-00398-8","journal-title":"Drugs Real World Outcomes"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2019.0208","article-title":"Use of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and abdominal obesity: an Asian perspective and expert recommendations","volume":"44","author":"Sheu WH","year":"2020","unstructured":"Sheu WH, Chan SP, Matawaran BJ, et al.. Use of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and abdominal obesity: an Asian perspective and expert recommendations. Diabetes Metab J. 2020, 44:11-32. 10.4093\/dmj.2019.0208","journal-title":"Diabetes Metab J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023","volume":"46","author":"ElSayed NA","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al.. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023, 46:S140-57. 10.2337\/dc23-S009","journal-title":"Diabetes Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_225_20","article-title":"RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020","volume":"24","author":"Chawla R","year":"2020","unstructured":"Chawla R, Madhu SV, Makkar BM, Ghosh S, Saboo B, Kalra S. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian J Endocrinol Metab. 2020, 24:1-122. 10.4103\/ijem.IJEM_225_20","journal-title":"Indian J Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-019-4119-9","article-title":"Enhancing knowledge and coordination in obesity treatment: a case study of an innovative educational program","volume":"19","author":"Osmundsen TC","year":"2019","unstructured":"Osmundsen TC, Dahl U, Kulseng B. Enhancing knowledge and coordination in obesity treatment: a case study of an innovative educational program. BMC Health Serv Res. 2019, 19:278. 10.1186\/s12913-019-4119-9","journal-title":"BMC Health Serv Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01748-0","article-title":"Practical approaches to treating obesity: patient and healthcare professional perspectives","volume":"38","author":"O'Shea D","year":"2021","unstructured":"O'Shea D, Kahan S, Lennon L, Breen C. Practical approaches to treating obesity: patient and healthcare professional perspectives. Adv Ther. 2021, 38:4138-50. 10.1007\/s12325-021-01748-0","journal-title":"Adv Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4103\/jod.jod_115_23","article-title":"Diabetes treatment with dapagliflozin and its combinations: insights from clinical practice","volume":"15","author":"Bafna A","year":"2024","unstructured":"Bafna A, Mehta A, Garg R, et al.. Diabetes treatment with dapagliflozin and its combinations: insights from clinical practice. J Diabetol. 2024, 15:183-92. 10.4103\/jod.jod_115_23","journal-title":"J Diabetol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5916.245303","article-title":"National ethical guidelines for biomedical & health research involving human participants, 2017: a commentary","volume":"148","author":"Mathur R","year":"2018","unstructured":"Mathur R, Swaminathan S. National ethical guidelines for biomedical & health research involving human participants, 2017: a commentary. Indian J Med Res. 2018, 148:279-83. 10.4103\/0971-5916.245303","journal-title":"Indian J Med Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino F","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, et al.. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025, 13:221-62. 10.1016\/S2213-8587(24)00316-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2023.100208","article-title":"Abdominal obesity in India: analysis of the National Family Health Survey-5 (2019-2021) data","volume":"14","author":"Chaudhary M","year":"2023","unstructured":"Chaudhary M, Sharma P. Abdominal obesity in India: analysis of the National Family Health Survey-5 (2019-2021) data. Lancet Reg Health Southeast Asia. 2023, 14:100208. 10.1016\/j.lansea.2023.100208","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"ref27","article-title":"Obesity and Type 2 Diabetes","author":"Yashi K","year":"2023","unstructured":"Yashi K, Daley SF. Obesity and Type 2 Diabetes. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref28","article-title":"BMI Classification Percentile and Cut Off Points","author":"Weir CB","year":"2023","unstructured":"Weir CB, Jan A. BMI Classification Percentile and Cut Off Points. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body\u2010mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"WHO Expert Consultation","year":"2004","unstructured":"WHO Expert Consultation. Appropriate body\u2010mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004, 363:157-63. 10.1016\/S0140-6736(03)15268-3","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022, 45:2753-86. 10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"ref31","article-title":"IDF Diabetes Atlas","author":"Magliano DJ","year":"2021","unstructured":"Magliano DJ, Boyko EJ. IDF Diabetes Atlas. International Diabetes Federation, Brussels; 2021."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1161521","article-title":"Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments","volume":"14","author":"Ruze R","year":"2023","unstructured":"Ruze R, Liu T, Zou X, et al.. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne). 2023, 14:1161521. 10.3389\/fendo.2023.1161521","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108389","article-title":"Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases","volume":"37","author":"Handelsman Y","year":"2023","unstructured":"Handelsman Y, Butler J, Bakris GL, et al.. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2023, 37:108389. 10.1016\/j.jdiacomp.2022.108389","journal-title":"J Diabetes Complications"},{"key":"ref34","unstructured":"NICE. Type 2 diabetes in adults. management. (2015). Accessed: June 26, 2025: https:\/\/www.nice.org.uk\/guidance\/ng28\/chapter\/Recommendations."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.4103\/cdrp.cdrp_8_23","article-title":"ADMIRE study: dapagliflozin and metformin fixed-dose combination as initial choice of therapy in type 2 diabetes mellitus: a real-world study","volume":"3","author":"Phadke U","year":"2024","unstructured":"Phadke U, Gopal J, Biswas K, Joshi P, Prasad A, Birla A. ADMIRE study: dapagliflozin and metformin fixed-dose combination as initial choice of therapy in type 2 diabetes mellitus: a real-world study. Chron Diabetes Res Pract. 2024, 3:27-32. 10.4103\/cdrp.cdrp_8_23","journal-title":"Chron Diabetes Res Pract"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad114.868","article-title":"FRI649 ADMIRE: assessing dapagliflozin and metformin as an initial regimen in diabetes mellitus for enhanced glucose control","volume":"7","author":"Phadke DU","year":"2023","unstructured":"Phadke DU, Gopal DJ, Biswas DK, Birla DA, Prasad A, Joshi P. FRI649 ADMIRE: assessing dapagliflozin and metformin as an initial regimen in diabetes mellitus for enhanced glucose control. J Endocr Soc. 2023, 7:bvad114.868. 10.1210\/jendso\/bvad114.868","journal-title":"J Endocr Soc"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0562-1","article-title":"Evidence-based consensus on positioning of SGLT2i in type 2 diabetes mellitus in Indians","volume":"10","author":"Singh AK","year":"2019","unstructured":"Singh AK, Unnikrishnan AG, Zargar AH, et al.. Evidence-based consensus on positioning of SGLT2i in type 2 diabetes mellitus in Indians. Diabetes Ther. 2019, 10:393-428. 10.1007\/s13300-019-0562-1","journal-title":"Diabetes Ther"},{"key":"ref38","unstructured":"Sodium-glucose cotransporter-2 (SGLT2) inhibitors. (2022). Accessed. June 26, 2025: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/sodium-glucose-cotransporter-2-sg...."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.20230090","article-title":"Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India","volume":"69","author":"Varshney A","year":"2023","unstructured":"Varshney A, Rawat R. Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India. Rev Assoc Med Bras (1992). 2023, 69:e20230090. 10.1590\/1806-9282.20230090","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_517_16","article-title":"Long-term efficacy and safety of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes in Indian subgroup: results from a 76-week extension trial of phase III, double-blind, randomized study","volume":"21","author":"Gupta S","year":"2017","unstructured":"Gupta S, Shaikh S, Joshi P, Bhure S, Suvarna V. Long-term efficacy and safety of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes in Indian subgroup: results from a 76-week extension trial of phase III, double-blind, randomized study. Indian J Endocrinol Metab. 2017, 21:286-92. 10.4103\/ijem.IJEM_517_16","journal-title":"Indian J Endocrinol Metab"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70780","article-title":"Patient adherence for oral combination therapies in diabetes management: a scoping review","volume":"8","author":"Zarrinkamar M","year":"2025","unstructured":"Zarrinkamar M, Geran M, Geran M. Patient adherence for oral combination therapies in diabetes management: a scoping review. Health Sci Rep. 2025, 8:e70780. 10.1002\/hsr2.70780","journal-title":"Health Sci Rep"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01382-9","article-title":"Real-world evaluation of GLP-1 receptor agonist therapy persistence, adherence and therapeutic inertia among obese adults with type 2 diabetes","volume":"14","author":"Palanca A","year":"2023","unstructured":"Palanca A, Ampudia-Blasco FJ, Calder\u00f3n JM, et al.. Real-world evaluation of GLP-1 receptor agonist therapy persistence, adherence and therapeutic inertia among obese adults with type 2 diabetes. Diabetes Ther. 2023, 14:723-36. 10.1007\/s13300-023-01382-9","journal-title":"Diabetes Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3791","article-title":"Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes","volume":"40","author":"Ciardullo S","year":"2024","unstructured":"Ciardullo S, Savar\u00e9 L, Rea F, Perseghin G, Corrao G. Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes. Diabetes Metab Res Rev. 2024, 40:e3791. 10.1002\/dmrr.3791","journal-title":"Diabetes Metab Res Rev"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e10904","article-title":"Health care delivery model in India with relevance to diabetes care","volume":"8","author":"Das AK","year":"2022","unstructured":"Das AK, Saboo B, Maheshwari A, et al.. Health care delivery model in India with relevance to diabetes care. Heliyon. 2022, 8:e10904. 10.1016\/j.heliyon.2022.e10904","journal-title":"Heliyon"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S008","article-title":"8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2021","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. 8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021, 44:S100-10. 10.2337\/dc21-S008","journal-title":"Diabetes Care"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association","year":"2024","unstructured":"American Diabetes Association. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2024. Diabetes Care. 2024, 47:S145-57. 10.2337\/dc24-S008","journal-title":"Diabetes Care"},{"key":"ref47","article-title":"A health care provider intervention to address obesity in patients with diabetes","volume":"36","author":"Boddu N","year":"2019","unstructured":"Boddu N, Abedzadeh-Anakari S, Chitharanjan D, Maraka S. A health care provider intervention to address obesity in patients with diabetes. Fed Pract. 2019, 36:16-8.","journal-title":"Fed Pract"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.18203\/2394-6040.ijcmph20212614","article-title":"Insights of healthcare providers and patients on implementation of dietary\/lifestyle intervention for reversal of obesity and type 2 diabetes: a qualitative study","volume":"8","author":"Lyngdoh T","year":"2021","unstructured":"Lyngdoh T, Sharma N, Zodpey S. Insights of healthcare providers and patients on implementation of dietary\/lifestyle intervention for reversal of obesity and type 2 diabetes: a qualitative study. Int J Community Med Public Health. 2021, 8:3533-40. 10.18203\/2394-6040.ijcmph20212614","journal-title":"Int J Community Med Public Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/353402-indian-clinicians-perspectives-on-utilizing-dapagliflozin-based-combination-therapy-for-the-management-of-obesity-in-patients-with-type-2-diabetes-mellitus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T06:01:08Z","timestamp":1758175268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/353402-indian-clinicians-perspectives-on-utilizing-dapagliflozin-based-combination-therapy-for-the-management-of-obesity-in-patients-with-type-2-diabetes-mellitus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.92594","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}